Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Pharma Mar SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Pharma Mar SA, Medical Devices Deals, 2011 to YTD 2017 10
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Pharma Mar SA, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Pharma Mar Enters into Agreement with Spanish National Cancer Research Centre 12
Merger 13
Zeltia Merges with Pharma Mar in Reverse Merger Transaction 13
Licensing Agreements 14
Pharma Mar to Enter into Licensing Agreement with Boryung Pharma 14
Boryung Pharm Enters into Licensing Agreement with Pharma Mar 15
Eczacibasi Enters into Licensing Agreement with Pharma Mar 16
Specialised Therapeutics Asia Enters into Licensing Agreement with Pharma Mar 17
Chugai Pharma Enters into Licensing Agreement with Pharma Mar 18
Boryung Pharma Enters into Licensing Agreement with Pharma Mar 19
Specialised Therapeutics Enters into Licensing Agreement with Pharma Mar 20
TTY Biopharm Enters into Licensing Agreement with PharmaMar 21
Specialised Therapeutics Enters into Licensing Agreement with Pharma Mar 22
PharmaMar Enters into Licensing Agreement with Chugai Pharma for Aplidin 23
PharmaMar Enters into Licensing Agreement with GP Pharm for Politrate Leuprorelin 24
PharmaMar Enters Into Licensing Agreement With Janssen Products For Yondelis 25
Alnylam Pharma Enters Into Option Licensing Agreement With Sylentis 26
Pharma Mar SA – Key Competitors 27
Pharma Mar SA – Key Employees 28
Pharma Mar SA – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 31
Financial Announcements 31
Oct 24, 2017: Pharma Mar group revenues totalled €140 million in the first nine months of the year 31
Jul 26, 2017: Pharma Mar group reports first half financial results 32
Apr 27, 2017: PharmaMar Group reports €45.5 million in revenues (+8%) 33
Feb 24, 2017: PharmaMar continues to execute commercially in 2016, adds new partner for pipeline asset, and sees pipeline progress 34
Oct 27, 2016: PharmaMar Group Reports 9M 2016 Financial Results 36
Jul 26, 2016: Pharma Mar Group Reports 1H 2016 Financial Results 37
Apr 28, 2016: PharmaMar Group Reports Q1 2016 Financial Results 38
Government and Public Interest 39
Mar 29, 2017: The success of sarcoma treatment, seen by prestigious international oncologists 39
Product News 41
12/01/2016: PharmaMar presents positive results with its conjugated antibody MI130110 in CD13-experssing tumor-cells 41
06/16/2017: PharmaMar Will Commercialize PM1183 With the Trade Name of Zepsyre 42
05/18/2016: Janssen to Present Data on Trabectedin at the 2016 American Society of Clinical Oncology Annual Meeting 43
05/06/2016: Early diagnosis, a multidisciplinary approach and access to new therapies, key in the treatment of ovarian cancer 44
04/27/2017: PharmaMar demonstrates its progress in R&D in New York 46
04/14/2016: PharmaMar Announces Presentation on Plitidepsin at American Association for Cancer Research (AACR) Annual Meeting 2016 47
04/14/2016: PharmaMar Announces Presentation on PM1183 at American Association for Cancer Research (AACR) Annual Meeting 2016 48
04/14/2016: PharmaMar Announces Presentation on PM184 at American Association for Cancer Research (AACR) Annual Meeting 2016 49
04/04/2017: PharmaMar Presents New Data on Lurbinectedin at the AACR Congress 50
03/03/2016: Yondelis Approved for Sale in 6 Additional Countries 51
Product Approvals 52
Oct 28, 2016: The EMA Accepts to Assess the Marketing Authorization Application from PharmaMar for Aplidin 52
Sep 22, 2016: PharmaMar submits MAA to EMA for Aplidin for the treatment of multiple myeloma 53
Clinical Trials 54
Sep 19, 2017: PharmaMar Starts Clinical Studies with a New Compound –PM14- in Patients with Solid Tumors 54
Jun 13, 2017: PharmaMar Announces Encouraging Results in Clinical Trials of Lurbinectedin in Endometrial and Breast Cancers 55
May 18, 2017: PharmaMar Announces new data on Lurbinectedin during ASCO 2017 56
Nov 28, 2016: PharmaMar Begins a Phase I studyof PM1183 in Japan for the Treatment of Solid Tumors 57
Nov 10, 2016: PharmaMar shows new clinical data on PM1183 (lurbinectedin) at CTOS 2016 58
Nov 10, 2016: PharmaMar shows new clinical data on Yondelis (trabectedin) at CTOS 2016 59
Oct 31, 2016: PharmaMar is present at the 16th International Gynecologic Cancer Society Meeting with new evidence on Yondelis 61
Oct 18, 2016: PharmaMar completes the patient recruitment for the “CORAIL” Phase III pivotal study with PM1183 62
Oct 10, 2016: PharmaMar Announces Positive Results From its Phase II Study With lurbinectedin in BRCA 1/2 – Associated Metastatic Breast Cancer at the ESMO 2016 Congress 63
Oct 05, 2016: PharmaMar announces new clinical data on lurbinectedin (PM1183) to be presented at ESMO 2016 64
Oct 05, 2016: PharmaMar announces new clinical data on Yondelis to be presented at ESMO 2016 66
Aug 11, 2016: PharmaMar Announces the IDMCs Response on the CORAIL Trial Using PM1183 67
Aug 02, 2016: PharmaMar initiates a pivotal Phase III ATLANTIS study with PM1183 in combination with doxorubicin in patients with small cell lung cancer 68
Jun 14, 2016: PharmaMar Announces the Start of a Pivotal Study With plitidepsin in angioimmunoblastic T-cell lymphoma 69
May 20, 2016: PharmaMar begins a Phase I study of lurbinectedin in combination with irinotecan for the treatment of solid tumors 70
May 19, 2016: PharmaMar Announces New Data on PM1183 to be Presented at 2016 ASCO Annual Meeting 71
May 19, 2016: PharmaMar Announces New Data on Yondelis at 2016 ASCO Annual Meeting 72
May 19, 2016: PharmaMar reports positive results from the Phase I study of Aplidin (plitidepsin) in combination with bortezomib and dexamethasone in patients with multiple myeloma at the 2016 ASCO Annual Meeting 73
Mar 31, 2016: Aplidin shows positive results in pivotal Phase III clinical trial for multiple myeloma 74
Feb 26, 2016: PharmaMar initiates a Phase II trial with antitumour drug PM184 in advanced breast cancer 75
Feb 08, 2016: The Phase III Clinical Trial Using PM1183 in Treating Ovarian Cancer Continues Following the IDMC’s Positive Recommendation 76
Other Significant Developments 77
Jun 29, 2017: PharmaMar Group reviews 2016 at its annual general shareholders meeting 77
Appendix 78
Methodology 78
About GlobalData 78
Contact Us 78
Disclaimer 78
Pharma Mar SA, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Pharma Mar SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Pharma Mar SA, Deals By Therapy Area, 2011 to YTD 2017 9
Pharma Mar SA, Medical Devices Deals, 2011 to YTD 2017 10
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Pharma Mar Enters into Agreement with Spanish National Cancer Research Centre 12
Zeltia Merges with Pharma Mar in Reverse Merger Transaction 13
Pharma Mar to Enter into Licensing Agreement with Boryung Pharma 14
Boryung Pharm Enters into Licensing Agreement with Pharma Mar 15
Eczacibasi Enters into Licensing Agreement with Pharma Mar 16
Specialised Therapeutics Asia Enters into Licensing Agreement with Pharma Mar 17
Chugai Pharma Enters into Licensing Agreement with Pharma Mar 18
Boryung Pharma Enters into Licensing Agreement with Pharma Mar 19
Specialised Therapeutics Enters into Licensing Agreement with Pharma Mar 20
TTY Biopharm Enters into Licensing Agreement with PharmaMar 21
Specialised Therapeutics Enters into Licensing Agreement with Pharma Mar 22
PharmaMar Enters into Licensing Agreement with Chugai Pharma for Aplidin 23
PharmaMar Enters into Licensing Agreement with GP Pharm for Politrate Leuprorelin 24
PharmaMar Enters Into Licensing Agreement With Janssen Products For Yondelis 25
Alnylam Pharma Enters Into Option Licensing Agreement With Sylentis 26
Pharma Mar SA, Key Competitors 27
Pharma Mar SA, Key Employees 28
Pharma Mar SA, Subsidiaries 29